التفاصيل البيبلوغرافية
| العنوان: |
Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. |
| المؤلفون: |
Li, Feng, Liao, Binchi, Wang, Ting, Qi, Tingting, Wang, Yixin |
| المصدر: |
Frontiers in Pharmacology; 6/16/2022, Vol. 13, p1-10, 10p |
| مصطلحات موضوعية: |
PEMBROLIZUMAB, NON-small-cell lung carcinoma, PROGRAMMED cell death 1 receptors, CELL death, PROGRAMMED death-ligand 1, CANCER research |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
PD-1/PD-L1 play key roles in tumor immune escape and the formation of the tumor microenvironment, and are closely related to the generation and development of tumors. Blocking the PD-1/PD-L1 pathway can reshape the tumor microenvironment or block the formation of the tumor microenvironment and enhance endogenous antitumor immune response. Clinical trials show that the treatment of non-small cell lung cancer (NSCLC) with PD-1/PD-L1 inhibitors has significant advantages. The review briefly describes these basic principles of the PD-1/PD-L1 pathway and action mechanism in the treatment of NSCLC. A summary of global PD-1/PD-L1 clinical trials and five PD-1/PD-L1 inhibitors approved by FDA, EMA and NMPA for advanced NSCLC were analyzed. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Pharmacology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder